According to the research report titled ‘Global Liquid Biopsy Market 2021-2028’, available with MarketStudyReport, global liquid biopsy market is anticipated to expand at a CAGR of 18.54% over the forecast timeframe 2021-2028.
 

As per report findings, escalating number of elderly breast and colorectal cancer patients is propelling worldwide liquid biopsy market growth. Furthermore, technological advancements and increasing need for diagnostics centers are likely to create new opportunities for organizations operating in this vertical.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3754634/
 

On the downside, the overall industry expansion may be hampered by scarcity of experienced specialists and expensive liquid biopsy testing.
 

Based on clinical application, the market is split into prognosis and reoccurrence monitoring, treatment monitoring, diagnosis and screening, and treatment selection. In terms of therapeutic application, the market is fragmented into lung cancer, prostate cancer, breast cancer, melanoma cancer, colorectal cancer, other cancer types, and non-oncology application.
 

With respect to biomarker type, the segmentation comprises nucleic acid, protein, cells, and extracellular vesicles. Coming to the product landscape, the bifurcation includes circulating tumor DNA (CTDNA), circulating tumor cells (CTCS), cell-free DNA (CFDNA), and extracellular vesicles and others. Moving on, the industry is segmented into hospitals, physicians’ office laboratories, and clinical diagnostic laboratories.
 

Geographically, global liquid biopsy market size spans across North America (U.S., Canada), Europe (UK, Germany, Spain, France, Russia, Italy), MEA (South Africa, Turkey, Saudi Arabia, UAE), Asia Pacific (Japan, China, South Korea, India, Australia, New Zealand), and Latin America (Mexico and Brazil).
 

Among the above-mentioned regions, Asia-Pacific industry is expected to grow at a rapid pace over 2021-2028, owing to growing population in countries like India and China, upsurge in healthcare expenditure, as well as rising awareness about the use of liquid biopsy.
 

Considering the competitive landscape, Menarini-Silicon Biosystems, Qiagen GmbH, Biocept Inc., Illumina Inc., Myriad Genetics Inc., Bio-Rad Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Personal Genome Diagnostics Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., Adaptive Biotechnologies, Becton Dickinson and Co., and F Hoffmann-La Roche AG are among the major companies impacting worldwide liquid biopsy market trends.